← Leaderboards
Michael Peter Motley
State University New York Stony Brook
$128,281
Attributed
$128,281
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $47.2K · FY2019–21$50K$37.5K$25K$12.5K$0
'19
'20
'21
Funding mix
By agency
NIH$128,281 · 1
By mechanism
F30$128,281 · 1
Top collaborators
No co-investigators on record.
Most similar at State University New York Stony Brook
Same institution · by research overlap
- Janet K Leatherwood$3,814,520
- Dorothy S Lane$6,224,051
- Peter J Tonge$15,845,457
- Christopher W Cutler$6,543,935
- David G Thanassi$14,588,352
Others in their field
Other Emerging Leaders on “Antibiotic Resistance”
- Urs Ochsner · Crestone, Inc.$36,950,837
- Ryan Cirz · Revagenix, Inc.$35,410,554
- Daniel Pevear · Venatorx Pharmaceuticals, Inc.$25,064,821
- Bruce Blough · Research Triangle Institute$19,880,022
- Thomas Dick · Rbhs-New Jersey Medical School$15,241,285
- Terry Roemer · Prokaryotics, Inc.$13,917,276
Research focus
Antibiotic ResistanceAntibioticsAntibodiesAntibody-Mediated ProtectionAnti-Infective AgentsAntimicrobialBacteriaBaseBindingBloodCapsuleCarbapenem ResistanceCollaborationsComplementEffectivenessEfficacy TestingEncapsulatedEpitopesExhibitsExperimental StudyFc ReceptorFecesFightingAffect
Grant awards (3)
Studying the role of anti-capsular antibodies in mediating pathogenesis of carbapenem-resistant Klebsiella pneumoniae$46,035
F30 · FY2021 · AI · contact PI
Studying the role of anti-capsular antibodies in mediating pathogenesis of carbapenem-resistant Klebsiella pneumoniae$47,235
F30 · FY2020 · AI · contact PI
Studying the role of anti-capsular antibodies in mediating pathogenesis of carbapenem-resistant Klebsiella pneumoniae$35,011
F30 · FY2019 · AI · contact PI